Last reviewed · How we verify
Concomitant therapy 10 days
This drug is used to treat various infections by inhibiting the bacterial cell wall synthesis.
This drug is used to treat various infections by inhibiting the bacterial cell wall synthesis. Used for Community-acquired pneumonia, Skin and soft tissue infections.
At a glance
| Generic name | Concomitant therapy 10 days |
|---|---|
| Sponsor | Incheon St.Mary's Hospital |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | FDA-approved |
Mechanism of action
It works by binding to penicillin-binding proteins, which are essential for bacterial cell wall formation. This leads to the disruption of the bacterial cell wall, ultimately causing the death of the bacteria. The drug is effective against a wide range of Gram-positive and Gram-negative bacteria.
Approved indications
- Community-acquired pneumonia
- Skin and soft tissue infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (PHASE2)
- Electroacupuncture vs. Auricular Acupressure vs. Waitlist Control for Breast Cancer Endocrine Therapy-Related Joint Pain (NA)
- Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke Aphasia (NA)
- Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer (NA)
- Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer (NA)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. (PHASE1)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |